Clinical Trial: A First-in Human Study of ARD001 in Healthy Volunteers and People With Hemophilia A

U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07787091) titled 'A First-in Human Study of ARD001 in Healthy Volunteers and People With Hemophilia A' on Aug. 02.

Brief Summary: This study is evaluating ARD001, an investigational medicine being developed for the treatment of hemophilia A. In Phase 1, healthy adult participants will receive a single dose of ARD001 or placebo to assess its safety and tolerability, how it moves through the body, its effects on blood coagulation, and whether the body develops antibodies against it.

If the Phase 1 results support further study and the required regulatory and ethics approvals are obtained, Phase 2 will evaluate repeated doses of ARD001 in adults with h...